Trial of INI-4001 in Patients With Advanced Solid Tumours

NCT06302426 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: INI-4001
COMBINATION_PRODUCT: Nivolumab
COMBINATION_PRODUCT: Pembrolizumab
COMBINATION_PRODUCT: Cemiplimab
COMBINATION_PRODUCT: Avelumab
COMBINATION_PRODUCT: Atezolizumab
COMBINATION_PRODUCT: Durvalumab

Sponsor

Inimmune Corporation

Collaborators

Avance Clinical Pty Ltd.